Literature DB >> 18241079

The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.

M Ferracin1, R Gafà, E Miotto, A Veronese, C Pultrone, S Sabbioni, G Lanza, M Negrini.   

Abstract

The CpG island methylator phenotype (CIMP) in colorectal tumours can be recognized by an increased frequency of aberrant methylation in a specific set of genomic loci. Because of the strong association of CIMP with high microsatellite instability (MSI-H), the identification of CIMP+ tumours within microsatellite stable (MSS) colorectal cancers may not be straightforward. To overcome this potential limitation, we have built an improved seven-locus set of methylation markers that includes CACNA1G, IGF2, RUNX3, HTR6, RIZ1, MINT31, and MAP1B. This new set of CIMP markers revealed a bimodal distribution of methylation frequencies in a group of 95 MSS colorectal cancers, which allowed a clearer separation between CIMP classes. Correlation of MSS CIMP+ tumours with bio-pathological traits revealed significant associations with location to the proximal colon, mucinous histology, BRAF mutation, and chromosomal stability. A potential trend towards an adverse prognosis of CIMP+ cases was associated with the high frequency of BRAF mutations present within this cohort of tumours. Microarray analysis revealed that CIMP+ tumours are characterized by a unique expression profile, a result that confirms that CIMP+ tumours represent a truly distinct molecular class within MSS colorectal cancers. Copyright (c) 2008 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241079     DOI: 10.1002/path.2318

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Authors:  Rodrigo Jover; Thuy-Phuong Nguyen; Lucía Pérez-Carbonell; Pedro Zapater; Artemio Payá; Cristina Alenda; Estefanía Rojas; Joaquín Cubiella; Francesc Balaguer; Juan D Morillas; Juan Clofent; Luis Bujanda; Josep M Reñé; Xavier Bessa; Rosa M Xicola; David Nicolás-Pérez; Antoni Castells; Montserrat Andreu; Xavier Llor; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-12-24       Impact factor: 22.682

2.  Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.

Authors:  Noriko Tanaka; Curtis Huttenhower; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; John Quackenbush; Kevin M Haigis; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

4.  Concerns and challenges in flexible sigmoidoscopy screening.

Authors:  Akeem O Adebogun; Christine D Berg; Adeyinka O Laiyemo
Journal:  Colorectal Cancer       Date:  2012-08

Review 5.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

6.  Is KRAS mutation associated with interval colorectal cancers?

Authors:  Aasma Shaukat; Mustafa Arain; Ruth Anway; Sharad Manaktala; Laurie Pohlman; Bharat Thyagarajan
Journal:  Dig Dis Sci       Date:  2011-12-03       Impact factor: 3.199

7.  Factors associated with the risk of adenoma recurrence in distal and proximal colon.

Authors:  Adeyinka O Laiyemo; Chyke Doubeni; Paul F Pinsky; V Paul Doria-Rose; Pamela M Marcus; Robert E Schoen; Elaine Lanza; Amanda J Cross
Journal:  Digestion       Date:  2013-03-15       Impact factor: 3.216

8.  Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.

Authors:  Scott C Borinstein; Melissa Conerly; Slavomir Dzieciatkowski; Swati Biswas; M Kay Washington; Patty Trobridge; Steve Henikoff; William M Grady
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

9.  Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.

Authors:  Pei Woon Ang; Marie Loh; Natalia Liem; Pei Li Lim; Fabienne Grieu; Aparna Vaithilingam; Cameron Platell; Wei Peng Yong; Barry Iacopetta; Richie Soong
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

Review 10.  Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?

Authors:  Barry Iacopetta; Kazuyuki Kawakami; Toshiaki Watanabe
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.